Napsin A Antibody (NAPSA/7165R) [DyLight 594]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-20977DL594
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunohistochemistry-Paraffin, Western Blot
Label
DyLight 594 (Excitation = 593 nm, Emission = 618 nm)
Antibody Source
Recombinant Monoclonal Rabbit IgG Kappa Clone # NAPSA/7165R
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Recombinant fragment (aa50-150) of human Napsin A protein (exact sequence is proprietary)
Localization
Cytoplasm.
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG Kappa
Applications for Napsin A Antibody (NAPSA/7165R) [DyLight 594]
Application
Recommended Usage
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Napsin A
Alternate Names
ASP4, KAP, NAPA, NAPSA, Napsin-1, SNAPA, TA01/TA02
Gene Symbol
NAPSA
Additional Napsin A Products
Product Documents for Napsin A Antibody (NAPSA/7165R) [DyLight 594]
Product Specific Notices for Napsin A Antibody (NAPSA/7165R) [DyLight 594]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...